Impact of PET and PET/CT Radiotracer for Evaluating Efficacy of CDK4/6 Inhibitor Therapy in HR-Positive HER2-Negative Metastatic Breast Cancer
Author:
Publisher
Springer Nature Switzerland
Link
https://link.springer.com/content/pdf/10.1007/978-3-031-49062-0_38
Reference14 articles.
1. Sung, H., Ferlay, J., Siegel, R.L. et al.: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71 (2021), pp. 209–249
2. Vandenberghe, S., Moskal, P., Karp, J.S.: State of the art in total body PET. EJNMMI Phys. 7, 35 (2020). https://doi.org/10.1186/s40658-020-00290-2
3. Ramos, N., et al.: Noninvasive PET imaging of CDK4/6 activation in breast cancer. J. Nucl. Med. 61(3), 437–442 (2020). https://doi.org/10.2967/jnumed.119.232603
4. Knudsen, E.S., Witkiewicz, A.K.: The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer 3(1), 39–55 (2017). https://doi.org/10.1016/j.trecan.2016.11.006
5. Roncato, R., et al.: CDK4/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions. Int. J. Mol. Sci. 21(17), 6350 (2020). https://doi.org/10.3390/ijms21176350
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3